{"id":"W2990936758","doi":"10.1093/annonc/mdz437.001","title":"Overall survival (OS) from the AURA3 phase III study: Osimertinib vs platinum-pemetrexed (plt-pem) in patients (pts) with EGFR T790M advanced non-small cell lung cancer (NSCLC) and progression on a prior EGFR-tyrosine kinase inhibitor (TKI)","year":2019,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":false,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Pemetrexed; Osimertinib; Internal medicine; T790M; Oncology; non-small cell lung cancer (NSCLC); Lung cancer; Phases of clinical research; Platinum; Chemotherapy; Cancer; Epidermal growth factor receptor; Cisplatin; Gefitinib; Erlotinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003016019,0.001419941,0.002573179,0.000462126,0.0004560989,0.001451456,0.0008189435,0.001281349,0.0029414],"category_scores_gemma":[0.001163102,0.0003916333,0.003888028,0.0006758973,0.0008064854,0.001154394,0.0006579311,0.003796276,0.0004856071],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009912835,"about_ca_system_score_gemma":0.001168144,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001701404,"about_ca_topic_score_gemma":0.004667683,"domain_scores_codex":[0.9993315,0.0003327478,0.00003969379,0.00008991413,0.0000578757,0.00014828],"domain_scores_gemma":[0.9990246,0.0002400753,0.0001780005,0.00006517748,0.00004169954,0.00045045],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9312052,0.003771411,0.01813067,0.0005611703,0.004394768,0.0001095357,0.0001073694,0.003189469,0.004381583,0.0001547093,0.003980108,0.03001399],"study_design_scores_gemma":[0.460048,0.3389151,0.1737391,0.0001881846,0.01172088,0.0005687081,0.0002591668,0.004328759,0.002673604,0.0009782914,0.006475353,0.0001048332],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9866366,0.00525282,0.000315992,0.0005791152,0.0002406714,0.0003139144,0.003672589,0.00004766205,0.002940636],"genre_scores_gemma":[0.9875591,0.00244034,0.0003004295,0.0008441592,0.0003363918,0.0003267526,0.006344458,0.00003819635,0.001810149],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003016019,"threshold_uncertainty_score":0.01595044,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02280830226885382,"score_gpt":0.3803921833819541,"score_spread":0.3575838811131003,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}